Elevance Health, Inc. $ELV Shares Sold by Vinva Investment Management Ltd

Vinva Investment Management Ltd lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 52.7% in the third quarter, HoldingsChannel.com reports. The fund owned 3,209 shares of the company’s stock after selling 3,569 shares during the quarter. Vinva Investment Management Ltd’s holdings in Elevance Health were worth $1,026,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Physician Wealth Advisors Inc. increased its holdings in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after purchasing an additional 63 shares during the period. Activest Wealth Management lifted its holdings in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares during the period. Rossby Financial LCC lifted its holdings in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the period. Vermillion & White Wealth Management Group LLC boosted its position in Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after buying an additional 37 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. acquired a new position in Elevance Health in the 2nd quarter worth approximately $32,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of NYSE ELV opened at $280.80 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The stock has a market capitalization of $61.98 billion, a price-to-earnings ratio of 11.18, a PEG ratio of 1.60 and a beta of 0.51. The firm’s 50 day simple moving average is $343.29 and its 200-day simple moving average is $335.14. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the previous year, the business posted $3.84 EPS. The business’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.5%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s payout ratio is currently 27.23%.

Analysts Set New Price Targets

Several analysts have commented on ELV shares. TD Cowen restated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Robert W. Baird increased their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $332.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a report on Tuesday, February 3rd. Finally, Leerink Partners increased their price target on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.